Corteva, Inc. (NYSE:CTVA) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Corteva, Inc. (NYSE:CTVA) has been given a consensus rating of “Moderate Buy” by the twenty-one analysts that are presently covering the stock, MarketBeat Ratings reports. Six analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and two have given a strong buy rating to the company. The average 12-month target price among analysts that have covered the stock in the last year is $81.8421.

Several equities research analysts have commented on CTVA shares. Royal Bank Of Canada upped their target price on shares of Corteva from $80.00 to $89.00 and gave the company an “outperform” rating in a research note on Thursday. Mizuho upped their price objective on shares of Corteva from $78.00 to $80.00 and gave the company an “outperform” rating in a research report on Friday, January 16th. Wells Fargo & Company lifted their target price on Corteva from $77.00 to $85.00 and gave the stock an “overweight” rating in a report on Thursday. Bank of America boosted their target price on Corteva from $80.00 to $82.00 and gave the company a “buy” rating in a research note on Thursday, January 8th. Finally, JPMorgan Chase & Co. lowered Corteva from an “overweight” rating to a “neutral” rating and raised their price target for the stock from $75.00 to $77.00 in a research report on Thursday.

Corteva Price Performance

Shares of CTVA opened at $72.50 on Friday. The stock has a market cap of $48.99 billion, a P/E ratio of 45.89, a price-to-earnings-growth ratio of 1.86 and a beta of 0.75. Corteva has a 1 year low of $53.40 and a 1 year high of $77.41. The stock’s 50-day moving average price is $68.72 and its two-hundred day moving average price is $68.43. The company has a current ratio of 1.43, a quick ratio of 1.07 and a debt-to-equity ratio of 0.07.

Corteva (NYSE:CTVA) last announced its quarterly earnings results on Tuesday, February 3rd. The company reported $0.22 EPS for the quarter, meeting analysts’ consensus estimates of $0.22. Corteva had a return on equity of 9.06% and a net margin of 6.29%.The company had revenue of $3.91 billion during the quarter, compared to analysts’ expectations of $4.23 billion. During the same period in the prior year, the business posted $0.32 EPS. Corteva’s revenue was down 1.7% on a year-over-year basis. Corteva has set its FY 2026 guidance at 3.450-3.700 EPS. On average, equities analysts predict that Corteva will post 2.96 earnings per share for the current year.

Corteva Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, March 16th. Investors of record on Monday, March 2nd will be paid a dividend of $0.18 per share. This represents a $0.72 dividend on an annualized basis and a yield of 1.0%. The ex-dividend date of this dividend is Monday, March 2nd. Corteva’s dividend payout ratio is presently 45.57%.

Key Corteva News

Here are the key news stories impacting Corteva this week:

• Positive Sentiment: RBC raised its price target to $89 and kept an “outperform” rating, signaling sizable upside from current levels and supporting bullish investor views. RBC raises price target
• Positive Sentiment: Management raised FY‑2026 EPS guidance to $3.45–$3.70 (above Street consensus ~3.23) and the company highlighted record free cash flow and a strong second half, which underpin longer‑term earnings visibility. Guidance and metrics Earnings highlights
• Neutral Sentiment: Analyst views are mixed across the sector, with some firms more cautious and others bullish — adding to day‑to‑day volatility as investors weigh differing valuations and demand outlooks. Conflicting analyst sentiments
• Neutral Sentiment: Full earnings materials and the call transcript are available; they show operational detail that investors will parse (product mix, regional timing) — useful for medium‑term positioning but containing both upside and downside signals. Earnings transcript
• Negative Sentiment: JPMorgan downgraded CTVA from “overweight” to “neutral,” citing limited valuation upside despite raising its target slightly to $77 — a headline catalyst for selling pressure. JPMorgan downgrade
• Negative Sentiment: Corteva missed Q4 revenue expectations as seasonal timing shifts and weaker crop protection/seed demand weighed, and the company reported a wider loss after hours — immediate negative for near‑term sentiment and the main driver of the intraday drop. Revenue miss article After-hours reaction

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Gladwyn Financial Advisors Inc. acquired a new stake in shares of Corteva during the second quarter worth $25,000. Activest Wealth Management raised its stake in shares of Corteva by 118.3% in the 3rd quarter. Activest Wealth Management now owns 369 shares of the company’s stock valued at $25,000 after purchasing an additional 200 shares during the period. JPL Wealth Management LLC bought a new stake in shares of Corteva in the third quarter valued at about $25,000. True Wealth Design LLC boosted its position in shares of Corteva by 209.5% during the third quarter. True Wealth Design LLC now owns 390 shares of the company’s stock worth $26,000 after buying an additional 264 shares during the period. Finally, Total Investment Management Inc. acquired a new position in shares of Corteva during the second quarter worth about $27,000. Institutional investors and hedge funds own 81.54% of the company’s stock.

Corteva Company Profile

Corteva, Inc (NYSE: CTVA) is an independent global agriculture company that was established as a publicly traded firm in mid‑2019 following the separation of the agriculture businesses from DowDuPont. The company focuses on delivering technologies and products that help farmers increase productivity and manage crop health. Corteva’s operations combine seed genetics, crop protection chemistries, digital tools and biological solutions to address the full cycle of crop production.

Core business activities include research and development of seed genetics and trait technologies, formulation and sale of crop protection products (such as herbicides, insecticides and fungicides), and the development of seed treatments and biologicals.